The subscription price in the private placement is NOK 1.00 per share.
Following the transaction the total number of shares outstanding in Hofseth BioCare ASA is 57,563,858 shares.
Dr. Bomi Framroze is Chief Scientific Officer in Hofseth BioCare ASA and primary insider in the company. Following the transaction, Framroze holds 200,000 shares in Hofseth BioCare ASA.
Under his option contract, Framroze has the right to subscribe for further 150,000 shares at subscription price of NOK 5.00 per share.
For more information please contact:
Sjur Jenssen, CEO Hofseth BioCare ASA
Tel: +47 9155 3514
Email: sj@h-bc.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. HBCs objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.